The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://macieupod204633.wikiannouncing.com/7582287/glp_3_retatrutide_a_comparative_analysis